Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Encephalitis, Tick-Borne
Phase 3: Encephalitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2018-004674-94 | P4 |
Active, not recruiting |
Encephalitis, Tick-Borne |
2024-04-05 |
|
2022-004181-37 | P3 |
Unknown status |
Encephalitis |
2018-09-22 |
|
TBE SEROPERSISTENCE AFTER FIRST BOOSTER IN CHILDREN (FOLLOW-UP TO STUDY 700401) | P4 |
Completed |
Encephalitis, Tick-Borne |
2017-05-10 |